Brentuximab Vedotin for Steroid Refractory GvHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01596218
Recruitment Status : Completed
First Posted : May 10, 2012
Last Update Posted : July 25, 2018
Seattle Genetics, Inc.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2016
  Actual Study Completion Date : December 2016